The Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for Ibrance to be used in combination with two existing therapies in women who have received prior endocrine therapy.
The CHMP's opinion will now be reviewed by the EMA, Pfizer said in a statement on Friday.
Ibrance, approved by the US Food and Drug Administration (FDA) in February 2015, contributed about half a billion dollars of Pfizer's total revenue of $13.1 billion in its latest quarter.
Pfizer's shares were off slightly in premarket trading on Friday.
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.